Rein Therapeutics Q2: Cash Runway to Q1 2028, IPF Trial Enrollment Ahead of Schedule
RNTX sits 22% above its 52-week low of $0.694.
Summary
Rein Therapeutics reported Q2 2026 results with a net loss of $6.4M, down from $6.8M a year ago, and cash of $43.6M, which funds operations into Q1 2028. The Phase 2 RENEW trial for LTI-03 in IPF has surpassed 25% enrollment of the planned 120 patients and is tracking ahead of schedule, with interim data expected in the second half of 2026. A peer-reviewed publication in Nature Communications on July 31 validated the drug's safety and biomarker reductions. The company completed a $57.5M oversubscribed offering in May, extending runway. This follows the 10-Q filed today, which also disclosed new warrant liabilities and ongoing material weaknesses in internal controls. The key near-term catalyst is the interim data readout later this year.
At the time of this announcement, RNTX was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.4M. The 52-week trading range was $0.69 to $2.18. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.